ArticlePediatric blood & cancer2010
Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program.
Article in Pediatric blood & cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 71 citations in OpenAlex.
- Cracking the shield: oncolytic viruses versus the tumor-immune fortress.Cancer cell international · 2026Review
- Engineered bacteria launch and control an oncolytic virus.Nature biomedical engineering · 2026Article
- Translation of oncolytic viruses in sarcoma.Molecular therapy. Oncology · 2024Review
- Engineering Non-Human RNA Viruses for Cancer Therapy.Vaccines · 2023Review
- Immunology Meets Bioengineering: Improving the Effectiveness of Glioblastoma Immunotherapy.Cancers · 2022Review
- Immunovirotherapy for Pediatric Solid Tumors: A Promising Treatment That is Becoming a Reality.Frontiers in immunology · 2022Review
- Progress of oncolytic virotherapy for neuroblastoma.Frontiers in pediatrics · 2022Review
- Evolving role of seneca valley virus and its biomarker TEM8/ANTXR1 in cancer therapeutics.Frontiers in molecular biosciences · 2022Review
- Tolerance of Senecavirus A to Mutations in Its Kissing-Loop or Pseudoknot Structure Computationally Predicted in 3' Untranslated Region.Frontiers in microbiology · 2022Article
- Senecavirus A Entry Into Host Cells Is Dependent on the Cholesterol-Mediated Endocytic Pathway.Frontiers in veterinary science · 2022Article
- Article
- N-Linked Glycosylation on Anthrax Toxin Receptor 1 Is Essential for Seneca Valley Virus Infection.Viruses · 2021Article
- Senecavirus A- and Non-Infected Cells at Early Stage of Infection: Comparative Metabolomic Profiles.Frontiers in cellular and infection microbiology · 2021Article
- Review
- Oncolytic Virotherapy in Glioma Tumors.International journal of molecular sciences · 2020Review
- Oncolytic immunotherapy for metastatic cancer: lessons and future strategies.Annals of translational medicine · 2020Article
- Novel recombinant coxsackievirus B3 with genetically inserted basic peptide elicits robust antitumor activity against lung cancer.Cancer medicine · 2020Article
- Biological treatment of pediatric sarcomas by combined virotherapy and NK cell therapy.BMC cancer · 2019Article
- Developing Picornaviruses for Cancer Therapy.Cancers · 2019Review
- Seneca Valley virus attachment and uncoating mediated by its receptor anthrax toxin receptor 1.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 9 institutions in 1 country.
Funding
Abstract
backgroundSeneca Valley virus (NTX-010) is a non-recombinant, replication competent RNA virus that is undergoing phase 1 clinical trials in adults for tumors with neuroendocrine characteristics. Here we have evaluated the antitumor activity of NTX-010 administered systemically. PROCEDURES: In vitro NTX-010 was tested against 23 cell lines exposed for 96 hr at 1 x 10(-4) to 10(4) viral particles (vp)/cell. In vivo NTX-010 was administered intravenously once at 3 x 10(12) vp/kg. Three measures of antitumor activity were used: (1) an objective response measure modeled after the clinical setting; (2) a treated to control (T/C) tumor volume measure; and (3) a time to event (fourfold increase in tumor volume for solid tumor models), measure based on the median event-free survival (EFS) of treated and control animals for each xenograft.
resultsIn vitro NTX-010 demonstrated a marked cytotoxic effect in a subset of the cell lines from the neuroblastoma, Ewing sarcoma, and rhabdomyosarcoma panels. In vivo the most consistent activity was observed for the rhabdomyosarcoma and the neuroblastoma panels, with all four of the alveolar rhabdomyosarcoma xenografts and four of five neuroblastoma xenografts achieving CR or maintained CR. Objective responses were also observed in the rhabdoid tumor, Wilms tumor, and glioblastoma panels.
conclusionsNTX-010 demonstrated a high level of activity both in vitro and in vivo. Further analysis of existing testing and molecular characterization data may help define the biological characteristics of cancer cells that are associated with response to NTX-010.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.